THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS INC (EIN 522029696) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1997

Legal Domicile

Principal Officer

THOMAS SUTULA

Phone

8332736800

Tax Period

2024-01-01 to 2024-12-31

THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS INC, founded in 1997, is a small nonprofit in the Community Improvement sector that reported $340K in total revenue in fiscal year 2024. Revenue fell 33% from the prior year — a significant decline worth monitoring. Expenses of $497K exceeded revenue, resulting in a 46% operating deficit.

Mission

ENCOURAGE AND ADVANCE THE DEVELOPMENT OF IMPROVED THERAPIES FOR DISEASES AND DISORDERS OF THE NERVOUS SYSTEM.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $298,357

Program Service Revenue $41,500

Investment Income $31

Other Revenue $0

TOTAL REVENUE $339,888

Expense Breakdown

Grants Paid $0

Salaries & Benefits $158,000

Fundraising Expenses $0

Program Expenses $414,759

Other Expenses $339,283

TOTAL EXPENSES $497,283

Year-over-Year Comparison

	2024	2023	Change
Revenue	$339,888	$508,582	-0.3%
Expenses	$497,283	$393,047	+0.3%
Net Income	$-157,395	$115,535	-2.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

$132,000

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ANDREW J COLE MD	PRESIDENT	1.00	Officer Director	$0	$0	$0
LUDY SHIH MD	INCOMING PRESIDENT	1.00	Officer Director	$0	$0	$0
THOMAS P SUTULA MD	PAST PRESIDENT	1.00	Officer Director	$0	$0	$0
C ANTHONY ALTAR PHD	SPLICE THERAPEUTICS	1.00	Director	$0	$0	$0
ENRIQUE CARRAZANA MD	NEURELIS	1.00	Director	$0	$0	$0
AMY CHAPPEL MD	CONSULTANT	1.00	Director	$0	$0	$0
GAIL FARFEL PHD	CONSULTANT	1.00	Director	$0	$0	$0
ADITYA JOSHI MD	UNIVERSITY OF PENN	1.00	Director	$0	$0	$0
DIETRICH HAUBENBERGER MD	NEUROCRINE	1.00	Director	$0	$0	$0
KAZUO FUJIHARA MD	FUKUSHIMA UNIVERSITY	1.00	Director	$0	$0	$0
DEBRA EHRLICH MD	NIH/NINDS	1.00	Director	$0	$0	$0
KENNETH SOMMERVILLE MD	SOMMERVILLE CONSULTING	1.00	Director	$0	$0	$0
SHARON TAMIR	CONSULTANT	1.00	Director	$0	$0	$0
AMIR TAMIZ PHD	NINDS/NIH LIAISON	1.00	Director	$0	$0	$0
M MARAL MOURADIANMD	JOURNAL EDITOR IN CHIEF	10.00	Key Emp	$36,000	$0	$36,000
JESSICA SMITH	EXECUTIVE DIRECTOR	32.00	Key Emp	$96,000	$0	$96,000

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$339,888	$497,283	$98,340	$-157,395
2023	$508,582	$393,047	$255,735	$115,535
2022	$236,991	$430,354	$128,237	$-193,363
2021	$287,384	$254,116	$321,598	$33,268
2020	$313,990	$375,701	$288,329	$-61,711
2019	$320,803	$343,354	$350,038	$-22,551
2018	$479,029	$397,419	$167,589	$81,610

THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS INC